Sarepta (SRPT) Q2 FY26 earnings call

Sarepta Therapeutics reported a financially strong second quarter, marked by operating profitability and increased cash, enabling independent advancement of its pipeline. While ELEVIDYS adoption and exon-skipping competition remain concerns, the company is focused on commercial execution and anticipates significant data readouts from its siRNA programs and Duchenne regulatory decisions. The core strategy emphasizes biology-driven innovation and disciplined capital allocation to drive future growth.